Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects

Fig. 1

Overall survival (OS) of all patients. The median OS is 26 months (95 % CI: 17.5–34.5 months). The 2-year OS and 5-year OS are 60.7 and 15.2 %, respectively. These results are favorable although all patients having metastases or recurrences

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us